At ImmunoKey we are developing a next generation CAR T-cell therapy platform designed to overcome the challenges of treating solid tumours.

Whilst CAR T-cell therapies have revolutionised the treatment of blood cancers, their effectiveness against solid tumours has been limited by several aspects of tumour biology.

ImmunoKey’s CARKey™ platform is designed to overcome critical limitations of existing CAR T-cell therapies. This widely applicable platform technology will underpin a pipeline of innovative cell therapies aimed at delivering effective treatments for cancer patients.